StockData
XTL Biopharmaceuticals Ltd logo

XTL Biopharmaceuticals Ltd (XTLB) stock

XTLBNasdaqPharmaceutical Preparations
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 30, 2026Score 0/30
$1.62+0.08 (+5.19%)

Close on Nov 17, 2026Market cap $15.33MP/E –Yield –

XTL Biopharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was -$1.69M. The highest annual figure on record is -$765.00K in fiscal 2023.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$1.69M–
FY2024Dec 31, 2024-$775.00K–
FY2023Dec 31, 2023-$765.00K–
FY2022Dec 31, 2022-$880.00K–
FY2021Dec 31, 2021-$1.03M–
FY2020Dec 31, 2020-$948.00K–
FY2019Dec 31, 2019-$842.00K–
FY2018Dec 31, 2018-$793.00K–
FY2017Dec 31, 2017-$1.25M–
FY2016Dec 31, 2016-$2.56M–
FY2015Dec 31, 2015-$3.61M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2022Jun 30, 2022-$202.00K–
Q2 FY2021Jun 30, 2021-$303.00K–
Q2 FY2020Jun 30, 2020-$217.00K–

More XTL Biopharmaceuticals figures

See a number that looks wrong?